S. Rousey

发表

Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases

B. Erickson, N. Janjan, P. Ritch, 1991, Journal of Neuro-Oncology.

Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.

M. Neubauer, L. Asmar, S. Mull, 2006, Clinical genitourinary cancer.

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

J. Ajani, A. Bleyer, James C Yao, 2006, Investigational New Drugs.

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.

J. Bennett, M. Tallman, G. Dewald, 2006, Haematologica.

Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation.

M. Gottlieb, R. Ash, S. Russler, 1991, The American journal of medicine.

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.

G. Sonpavde, M. Galsky, D. V. Von Hoff, 2011, Urologic oncology.

A fatal case of low titer anti‐PR cold agglutinin disease

RoyG. Smith, S. Rousey, 1990, American journal of hematology.

A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia.

E. Shaw, A. Falsey, J. Krauss, 2012, The journal of supportive oncology.

Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

G. Sonpavde, M. Galsky, D. Martincic, 2012, Clinical genitourinary cancer.

Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).

J. Manola, G. Wilding, M. Carducci, 2015, Clinical genitourinary cancer.

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

E. Perez, S. Nair, T. Hobday, 2005 .

Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

C. Obasaju, M. Socinski, T. Stinchcombe, 2008 .

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

Helen X. Chen, A. El-Khoueiry, T. Bekaii-Saab, 2015, Investigational New Drugs.

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

C. Obasaju, M. Socinski, D. Patt, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.